Attention deficit hyperactivity disorder (ADHD) is the most common childhood psychiatric disorder. It is significantly more common in boys than girls, with a male to female ratio of 3:1 and a prevalence rate of 4 to 6 percent. The core symptoms are inattention, hyperactivity and impulsivity. Inattentiveness can manifest itself in behaviors such as inability to sit quietly in class and listening to a lesson and interfering with others. Hyperactivity and impulsivity are signs of impaired inhibition, and impulsivity includes behavioral and cognitive impulses (related to school). Professor Jin Xingming of the Shanghai Jiaotong University Children’s Medical Center points out that since there is no standardized indicator for the cure of ADHD patients, many doctors often stop at the “response” of the patient, i.e., the improvement and reduction of symptoms. However, at this point, the patient may still have severe disease symptoms that affect the patient’s functional recovery. Therefore, “remission” should be the main goal of ADHD treatment and clinical research. What is “remission”? The term “remission” has three meanings: 1. The disappearance of symptoms or the basic absence of symptoms after treatment. Minimization of symptoms, from “always there” to “occasionally there”. 3. The patient achieves maximum functional recovery and is no longer diagnosed with ADHD. The main shortcomings of current clinical treatment are: more satisfied with “effective”; lack of re-evaluation during treatment; preference for small doses; and fear of optimal doses. These lead to a lack of better control of the patient’s condition and a failure to achieve the goal of “remission”. Scale scores. The SNAP-IV scale can be used during treatment to determine whether the patient is in remission to the extent of symptom minimization or asymptomatic. The SNAP-IV scale provides a more comprehensive and objective assessment of whether the patient’s treatment is effective or in clinical remission by assessing each of the 26 items (e.g., difficulty concentrating on work or play activities, rushing to answer questions before they are finished, etc.). Standardize medication use. Treatment of ADHD is a long-term process. The first-line medication recommended in China’s “Guidelines for the Treatment of Attention Deficit Hyperactivity Disorder” is the long-acting preparation methylphenidate hydrochloride controlled-release tablets (Focused), which has a rapid onset of action and sustained efficacy. Conventional medications require multiple doses a day and have poor adherence. Methylphenidate controlled-release tablets require only one dose a day and have good compliance. The medication should be administered at an appropriate starting dose and then titrated to optimal efficacy. Regular follow-up. A course of treatment is evaluated and the dose is adjusted accordingly, usually from 18 mg to 36 mg gradually, with a maximum dose of 54 mg.